[Form 3] ALNYLAM PHARMACEUTICALS, INC. Initial Statement of Beneficial Ownership

Rhea-AI Filing Summary

ALNYLAM PHARMACEUTICALS, INC. (ALNY) Form 3 filed for Bryan Supran, who is identified as Executive Vice President, Chief Legal Officer and Secretary. The event date requiring the statement is 09/15/2025. The filing states that no securities are beneficially owned by the reporting person and attaches Exhibit 24 (Power of Attorney). The form is signed by an attorney-in-fact on behalf of Mr. Supran on 09/22/2025.

Positive

• Initial Form 3 filed identifying reporting person and official role (EVP, CLO and Secretary).
• Explicit statement that no securities are beneficially owned, simplifying immediate disclosure requirements.
• Exhibit 24 (Power of Attorney) included and form executed by attorney-in-fact, which documents signature authority.

Negative

• None.

Insights

Corporate Governance Expert

TL;DR: Routine Form 3 disclosing an officer with no beneficial ownership; administrative and governance disclosure is complete.

The filing is a standard initial Section 16 disclosure identifying Bryan Supran as EVP, CLO and Secretary for Alnylam and reporting that he holds no beneficial ownership of issuer securities as of the event date. The inclusion of Exhibit 24 indicates a power of attorney was used for signature, which is common when filings are executed by counsel. There are no derivative or non-derivative positions reported, so there are no immediate equity-related conflicts or insider holding disclosures to evaluate.

Securities Compliance Analyst

TL;DR: Compliance filing appears complete and routine; no holdings reported reduces immediate insider-trading disclosure complexity.

This initial Form 3 lists the required issuer, reporting person, role and event date and explicitly states no securities are beneficially owned. The form was signed by an attorney-in-fact (Brett Budzinski) on behalf of the reporting person, and Exhibit 24 (Power of Attorney) is noted, satisfying signature delegation disclosure. No amendments or additional schedules are present.

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

SUPRAN BRYAN

(Last) (First) (Middle)

675 WEST KENDALL STREET

HENRI A. TERMEER SQUARE

(Street)

CAMBRIDGE MA 02142

(City) (State) (Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
09/15/2025

3. Issuer Name and Ticker or Trading Symbol
ALNYLAM PHARMACEUTICALS, INC. [ ALNY ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP, CLO and Secretary

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

Exhibit List: Exhibit 24 - Power of Attorney

No securities are beneficially owned.

	By: Brett Budzinski, Attorney-in-Fact For: Bryan Supran	09/22/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What does the ALNY Form 3 filed for Bryan Supran disclose?

The filing discloses that Bryan Supran, identified as EVP, CLO and Secretary of Alnylam, filed an initial Form 3 and reports no beneficial ownership of company securities.

What is the event date on the Form 3 for ALNY (Bryan Supran)?

The event date requiring the statement is 09/15/2025.

Was the Form 3 signed directly by Bryan Supran?

No. The form shows it was signed by Brett Budzinski, Attorney-in-Fact for Bryan Supran on 09/22/2025, and Exhibit 24 (Power of Attorney) is listed.

Does the Form 3 report any derivative or non-derivative holdings for ALNY?

No. The filing states no securities are beneficially owned and contains no entries in Table I or Table II.

Is there any amendment indicated on this Form 3?

No amendment date is provided on the form; it is presented as the initial filing.